Equillium Inc. (EQ)’s Financial Results Comparing With Shire plc (NASDAQ:SHPG)

Both Equillium Inc. (NASDAQ:EQ) and Shire plc (NASDAQ:SHPG) are each other’s competitor in the Biotechnology industry. Thus the compare of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Equillium Inc. N/A 0.00 9.82M -0.71 0.00
Shire plc N/A 0.00 N/A 7.94 21.44

Demonstrates Equillium Inc. and Shire plc earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Equillium Inc. 0.00% 0% 0%
Shire plc 0.00% 13% 7.2%

Liquidity

1.9 and 1.9 are the respective Current Ratio and a Quick Ratio of Equillium Inc. Its rival Shire plc’s Current and Quick Ratios are 0.9 and 0.5 respectively. Equillium Inc. has a better chance of clearing its pay short and long-term debts than Shire plc.

Dividends

Shire plc has an annual dividend pay of $0.35 per share while its annual dividend yield is 0.2%. Equillium Inc. does not offer a dividend.

Analyst Ratings

In next table is delivered Equillium Inc. and Shire plc’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Equillium Inc. 0 0 0 0.00
Shire plc 0 1 0 2.00

Competitively Shire plc has a consensus price target of $196, with potential upside of 9.38%.

Insider and Institutional Ownership

Institutional investors held 0.99% of Equillium Inc. shares and 22.9% of Shire plc shares. Insiders held roughly 21.3% of Equillium Inc.’s shares. Comparatively, Shire plc has 0.1% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Equillium Inc. -14.15% -17.66% 0% 0% 0% 0.57%
Shire plc -3.11% -5.99% 1.27% 6.01% 18.67% 9.67%

For the past year Equillium Inc.’s stock price has smaller growth than Shire plc.

Summary

Shire plc beats on 8 of the 9 factors Equillium Inc.

Equillium, Inc., a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1 clinical trials for the treatment of acute graft-versus-host disease and asthma. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was founded in 2017 and is headquartered in San Diego, California.

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE and ADYNOVATE/ADYNOVI for hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand Disease; FEIBA to treat hemophilia A and B patients with inhibitors; CINRYZE and FIRAZYR for hereditary angioedema; ELAPRASE to treat hunter syndrome; REPLAGAL for Fabry disease; and VPRIV to treat type 1 Gaucher disease. The company marketed products also comprise of VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention-deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of LIALDA/MEZAVANT for ulcerative colitis; GATTEX/REVESTIVE to treat short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA to treat dry eye disease. The company markets its products through wholesalers, distribution centers, and pharmacies. It has collaborative and other licensing arrangements with Pfizer Inc.; Precision BioSciences; Symphogen; Merrimack Pharmaceuticals, Inc.; Coherus Biosciences, Inc.; Momenta Pharmaceuticals, Inc.; and SFJ Pharmaceuticals Group. Shire plc was founded in 1986 and is based in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.